Modality
ERT
MOA
HPK1i
Target
TYK2
Pathway
Tau
WMEndometrial Ca
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Sep 2027
Phase 1Current
NCT06905735
1,301 pts·Endometrial Ca
2021-02→2027-09·Recruiting
NCT04366048
1,302 pts·Endometrial Ca
2017-12→2027-09·Terminated
2,603 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-021.4y awayPh2 Data· Endometrial Ca
2027-09-181.5y awayPh2 Data· Endometrial Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Termina…
P1/2
Recruit…
Catalysts
Ph2 Data
2027-09-02 · 1.4y away
Endometrial Ca
Ph2 Data
2027-09-18 · 1.5y away
Endometrial Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06905735 | Phase 1/2 | Endometrial Ca | Recruiting | 1301 | PFS |
| NCT04366048 | Phase 1/2 | Endometrial Ca | Terminated | 1302 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |